Fennec Pharmaceuticals Inc. (NASDAQ: FENC)

Fennec Pharmaceuticals Inc., with the stock symbol FENC, is a commercial-stage biopharmaceutical company operating in the healthcare sector, specifically within the pediatric oncology segment. The company's primary focus is on the development and commercialization of PEDMARK, a unique formulation of sodium thiosulfate for the prevention of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic solid tumors.

Fennec Pharmaceuticals Inc. generates revenue primarily through the sale of PEDMARK, the first and only FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic solid tumors. PEDMARK is a single-dose, ready-to-use vial for intravenous use in pediatric patients. The pediatric oncology segment is a critical market for PEDMARK, as it is the only FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic solid tumors. This segment is characterized by a high unmet medical need, as there are currently no established preventive agents for ototoxicity associated with cisplatin treatment.

In June 2023, PEDMARQSI, the European brand name for PEDMARK, received European Commission marketing authorization, making it the first and only approved therapy in the EU for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic solid tumors.

Fennec Pharmaceuticals Inc. has several competitive advantages that differentiate it from its competitors. Firstly, PEDMARK is the only FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic solid tumors. Secondly, the company has a strong intellectual property position, with several patents and patent applications covering PEDMARK. Finally, the company has a experienced field force and a comprehensive single-source program, Fennec HEARS, which provides patient financial and product access support.

The company's customers are primarily pediatric oncology centers and hospitals, as well as government agencies responsible for healthcare in various countries. Fennec Pharmaceuticals Inc. has established relationships with these customers and provides them with education and support to ensure that PEDMARK is used effectively and safely.

In terms of intellectual property, the company relies on a combination of patents, patent applications, and trade secrets to protect its intellectual property. The company has several patents and patent applications covering PEDMARK, including U.S. patents 11,291,728, 11,510,984, and 11,617,793, as well as several pending applications. The company also has a license agreement with Oregon Health & Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including PEDMARK.

Fennec Pharmaceuticals Inc. is subject to various laws and regulations, including the Orphan Drug Act, the Prescription Drug Marketing Act, and anti-kickback and false claims laws. The company is also subject to FDA regulations, including those related to clinical trials, marketing approval, and labeling. The company is required to comply with Good Manufacturing Practices (cGMP) and is subject to periodic inspections by the FDA and other authorities.